CMS Open Payments · Program Year 2024
Olympus Winter & Ibe GmbH
Olympus Winter & Ibe GmbH reported $34,399.20 across General Payments, Research, and Ownership to 14 physicians and teaching hospitals across 14 transactions.
- $34.4K Below-median payer
- All-tracks total
- 14 Below-median volume
- Transactions
- 14 Below-median reach
- Recipients
- +$29.6K
- General Payments vs PY2023
Olympus Winter & Ibe GmbH reported $34,399.20 across all CMS Open Payments tracks (General + Research + Ownership) to 14 physicians and teaching hospitals in Program Year 2024 - ranking #1442 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $34,399.20, averaging $2.5K per recipient.
How Olympus Winter & Ibe GmbH's $34.4K all-tracks total breaks down
Olympus Winter & Ibe GmbH's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
20/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer olympus-winter-ibe-gmbh Olympus Winter & Ibe GmbH
$34.4K · #1442/1,925 · 0.0% industry · PY2024
- TOT $34.4K
- RANK #1442
- SHARE 0.0%
- TXN 14
- RCP 14
- CAT 4
- GEN $34.4K
- ΔGEN +$29.6K
- TOP1 70.6%
- PY 2024
Volume peers
Nearest volume peer: MediView XR, Inc. ($34.4K)
Olympus Winter & Ibe GmbH sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Olympus Winter & Ibe GmbH's CMS-reported General Payments increased by $29.6K (+611.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OLYMPUS WINTER & IBE GMBHPY2023: OLYMPUS WINTER & IBE GMBHPY2024: Olympus Winter & Ibe GmbH. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $4,836.47
- PY2024
- $34,399.20
What the Data Shows for Olympus Winter & Ibe GmbH
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Olympus Winter & Ibe GmbH, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Acquisitions" at $24.3K, accounting for 70.6% of this company's General Payments and 1 transactions.
General Payment Breakdown by Type
Olympus Winter & Ibe GmbH made 4 types of general payments. "Acquisitions" is the largest category at $24.3K, 70.6% of General Payments.
Olympus Winter & Ibe GmbH reports 4 general-payment categories - the top three are Acquisitions (70.6%), Consulting Fee (28.7%), and Travel and Lodging (0.5%). The remaining 1 category make up 0.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Olympus Winter & Ibe GmbH divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Acquisitions | $24.3K | 1 | 70.6% |
| Consulting Fee | $9.9K | 10 | 28.7% |
| Travel and Lodging | $175.54 | 1 | 0.5% |
| Food and Beverage | $66.34 | 2 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $28,659.36 (83.3%) of $34,399.20 in this company's General Payments records across 11 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Olympus Winter & Ibe GmbH
The five named recipients with the highest reported General Payments from this company
- 1
Timothy Brian Mckinney
$24,273.02 across 1 reported transactions
- 2
Bilal I Chughtai
$1,146.34 across 3 reported transactions
- 3
Mantu B Gupta
$1,080.00 across 1 reported transactions
- 4
Brian H Eisner
$1,080.00 across 1 reported transactions
- 5
Max R Kates
$1,080.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Olympus Winter & Ibe GmbH ranks #1442 of 1,925 by total payments (bottom 25% by spend) but is notably more concentrated than that alone would suggest -- #350 of 1,838 by HHI (top 19% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- RxSight Inc : $11.1M total payments, HHI 5097
- Strategic Dentistry LLC : $1.7K total payments, HHI 5083
- Genmab BV : $51.5K total payments, HHI 5080
- Amnio Technology, LLC : $11.7K total payments, HHI 5078
- New Age Medical LLC : $137.0K total payments, HHI 5077
- Infinity BiologiX LLC : $52.4K total payments, HHI 5072
- Olympus Winter & Ibe GmbH (this company) : $34.4K total payments, HHI 5067
- Intellijoint Surgical Inc. : $32.2K total payments, HHI 5059
- McKesson Corporation : $98.3K total payments, HHI 5044
- Teleflex Incorporated : $670.6K total payments, HHI 5042
- nView medical, Inc : $169.96 total payments, HHI 5033
- Asuragen, Inc. : $4.9K total payments, HHI 5032
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Olympus Winter & Ibe GmbH's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Olympus Winter & Ibe GmbH.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Olympus Winter & Ibe GmbH.
Showing 6 of 1,924 companies with CMS-reported payment data.
Cycle Pharmaceuticals Inc
ZSFab, Inc.
Dentsply Sirona Pty Limited
Active Medical, LLC
Captiox LLC
Put this to use
Olympus Winter & Ibe GmbH ranks #1442 of 1,925 by all-tracks total payments, led by "Acquisitions".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Acquisitions" spend across every manufacturer, not just Olympus Winter & Ibe GmbH. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.